Optimizerx Corporation (OPRX)
NASDAQ (CM) NASDAQ (CM) Primary 
OptimizeRx Corporation (OPRX) Q3 2024 Earnings Call Transcript
OptimizeRx Corporation (NASDAQ:OPRX ) Q3 2024 Results Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants William Febbo - Chief Executive Officer Edward Stelmakh - Chief Financial Officer and Chief Operational Officer Steve Silvestro - President Conference Call Participants Ryan Daniels - William Blair & Company, LLC Sean Dodge - RBC Capital Markets Kyle Bauser - B. Riley Securities David Grossman - Stifel Financial Constantine Davides - Citizens JMP Stephanie Davis - Barclays Operator Good afternoon, everyone, and thank you for joining OptimizeRx's Third Quarter Fiscal 2024 Earnings Call.
OptimizeRx Corp. (OPRX) Surpasses Q3 Earnings Estimates
OptimizeRx Corp. (OPRX) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.09 per share a year ago.
OptimizeRx (OPRX) Surges 19.8%: Is This an Indication of Further Gains?
OptimizeRx (OPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
OptimizeRx (OPRX) Moves 5.4% Higher: Will This Strength Last?
OptimizeRx (OPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Down -12.46% in 4 Weeks, Here's Why OptimizeRx (OPRX) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for OptimizeRx (OPRX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
OptimizeRx Corp. (OPRX) Tops Q2 Earnings Estimates
OptimizeRx Corp. (OPRX) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.07 per share. This compares to loss of $0.01 per share a year ago.
OptimizeRx Corp. (OPRX) Expected to Beat Earnings Estimates: Should You Buy?
OptimizeRx (OPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
